150 related articles for article (PubMed ID: 16166966)
1. COX-2 inhibitors and hypercoagulability.
Farkouh ME
Clin Adv Hematol Oncol; 2005 Jan; 3(1):35-6. PubMed ID: 16166966
[No Abstract] [Full Text] [Related]
2. [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
Jerie P
Cas Lek Cesk; 2005; 144(1):4. PubMed ID: 15789774
[No Abstract] [Full Text] [Related]
3. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
Hedner T; Himmelmann A
Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
[No Abstract] [Full Text] [Related]
4. [The rise and fall of Vioxx: society, values and their choice].
Caspi D
Harefuah; 2004 Nov; 143(11):770-1. PubMed ID: 15603261
[No Abstract] [Full Text] [Related]
5. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091
[No Abstract] [Full Text] [Related]
6. [Really only Vioxx?].
Heinzl S
Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
[No Abstract] [Full Text] [Related]
7. Patient empowerment: rofecoxib revisited.
Tannenbaum H
J Rheumatol; 2006 Jun; 33(6):1033-5. PubMed ID: 16755647
[No Abstract] [Full Text] [Related]
8. What happened to the coxibs on the way to the cardiologist?
Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
[No Abstract] [Full Text] [Related]
9. Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
Can Fam Physician; 2005 Feb; 51(2):212-3. PubMed ID: 15751564
[No Abstract] [Full Text] [Related]
10. Health Canada lukewarm on Vioxx panel findings.
Murray S
CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
[No Abstract] [Full Text] [Related]
11. Balancing risks and benefits in pain medicine: wither Vioxx.
Gallagher RM
Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
[No Abstract] [Full Text] [Related]
12. Intracranial hypertension induced by rofecoxib.
Jacob S; Rajabally YA
Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of cardiovascular events with coxibs and NSAIDs.
Scott DG; Watts RA
Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299
[No Abstract] [Full Text] [Related]
14. Discontinuation of Vioxx.
Nutt DJ
Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
[No Abstract] [Full Text] [Related]
15. Don't throw out the baby with the bathwater!
Kamen B; Kieran M
J Pediatr Hematol Oncol; 2005 Feb; 27(2):59-60. PubMed ID: 15701976
[No Abstract] [Full Text] [Related]
16. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
17. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten WW; Reiter S;
Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
[No Abstract] [Full Text] [Related]
18. [Severe acute cholestatic and cytolytic hepatitis induced by rofecoxib].
Ouar S; Bellaïche G; Belloc J; Tordjman G; Ley G; Slama JL
Gastroenterol Clin Biol; 2005 Apr; 29(4):471-2. PubMed ID: 15918218
[No Abstract] [Full Text] [Related]
19. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
Lynd LD; Marra CA; Najafzadeh M; Sadatsafavi M
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1172-80. PubMed ID: 20602338
[TBL] [Abstract][Full Text] [Related]
20. The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain.
Reuben SS
Acta Anaesthesiol Scand; 2005 Mar; 49(3):424; author reply 425. PubMed ID: 15752415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
